- Bristol-Myers Squibb (BMY) has filed for Japanese authorization of its daclatasvir and asunaprevir combination treatment for Hepatitis C.
- The move comes after the combo cured 84.7% of 222 patients after 24 weeks in a Phase III trial.
- In early 2014, Bristol wants to test the drugs in a combination with another medicine, BMS791325, over a 12-week period.
- Bristol-Myers submission is the first one that doesn't include the standard treatments interferon and ribavirin, which are difficult to tolerate. (PR)